System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Todor A Popov is an expert in Immunology at University Hospital St. Ivan Rilski (Bulgaria). As of October 2026, ScienceLeadR ranks Todor A Popov in the top 1% of experts worldwide for Hypersensitivity, Asthma and Lung Diseases, Obstructive. Todor A Popov has authored 239 publications, the most recent in 2026, and is an investigator in 27 clinical trials, 11 of them ongoing. SLR score: 1,101 (community average: 125). How the SLR is computed.

LeadR Profile

Todor A Popov University Hospital St. Ivan Rilski Bulgaria
1 101 ScienceLeadR Reputation 1101

Unlock

Register Login
Network Map

Immunology

Subspecialties: Pulmonology - Public Health - Critical Care

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1980 - 2026
Source: PubMed

University Hospital St. Ivan Rilski

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 239

Citations

Citations: 12 845 1st author: 49 Last author: 22 Unique author: 15

Main journals

Allergy 27
J Allergy Clin Immunol 26
Clin Transl Allergy 13
J Allergy Clin Immunol Pract 13
Mutat Res 13

Best Journals

N Engl J Med 2
Am J Respir Crit Care Med 1
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.
PMID 42628554 — injections, safety, dermatitis, injection site reaction, drug-related side effects and adverse reactions, therapeutics, dermatitis, atopic		Lancet Top journal20262
Severity of Reactions in Double-Blind Placebo-Controlled Food Challenges: New Insights From the EuroPrevall Outpatient Clinic Study.
PMID 42663073 — safety, dermatitis, hypersensitivity, ambulatory care facilities, anaphylaxis, ovum, food, immunity, outpatients		J Investig Allergol Clin Immunol20260
Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study.
PMID 42638984 — therapeutics, asthma		J Asthma Allergy20260
ARIA-EAACI 2025: Person-Centred, Digitally Enabled and Artificial Intelligence-Assisted Change Management in Airway Diseases: An OECD Best Practice for Integrated Care for Chronic Diseases.
PMID 42613592 — change management, intelligence, chronic disease, air, rhinitis, asthma, artificial intelligence		Clin Transl Allergy20260
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.
PMID 42090792 — safety, vaccines, polymerase chain reaction, rna, messenger, influenza, human, influenza vaccines, reverse transcriptase polymerase chain reaction, vaccine efficacy		N Engl J Med Top journal20260

Clinical Studies 27

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 2 10
Phase 3 10
Phase 4 5
N/A 1
Phase 1 1

By status:

Completed 11
Active not recruiting 7
Recruiting 3
Unknown 3
Terminated 2
Not yet recruiting 1

By type:

Interventional 26
Observational 1

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 0
multicentricup10 22

Main Topics

Ongoing Clinical Trials

11 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Long term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria
2025-522878-36-00 — safety, urticaria, therapeutics		Phase 3Not yet recruiting2026
Study Assessing the Long term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients with Uncontrolled Moderate to Severe Asthma
2024-513423-16-00 — lung, asthma		Phase 4Active not recruiting2022
A study to investigate the efficacy and safety of TRIV 509 compared with placebo in adults with moderate to severe atopic dermatitis
2025-522113-35-00 — safety, dermatitis, dermatitis, atopic, pharmacokinetics		Phase 2Active not recruiting2026
Dose finding study of LAD603 in adults with alopecia areata
2025-523342-27-00 — safety, alopecia areata, alopecia		Phase 2Recruiting2026
A Long Term Safety and Efficacy Study of Verekitug (UPB 101) in Adult Participants with Severe Asthma
2024-519469-23-00 — safety, therapeutics, asthma		Phase 2Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS